Spectrum Pharmaceuticals Inc(SPPI) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Spectrum Pharmaceuticals, Inc., a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNá, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Current Price

$3.47

RSI

76.270

Beta:

2.2289

December 31, 2020
-34.6M

-57.191 %
-41.893 %
2.320 %
-26.749 %

$2,255,000
$7,676,000
$10,087,000
$-1,561,000
$136,466,000
$162,556,000
-70.623 %
-23.902 %
746.188 %
-101.144 %
-16.050 %

$-160,928,000
$-121,897,000
$-122,642,000
$-114,130,000
$-72,083,000
$-50,379,000
-32.020 %
0.607 %
-7.458 %
-58.331 %
-43.081 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.